Therefore, a colorectal tumor should meet at least two characteristics to become a responder to anti-PD1 treatment an anti-PD1 treatment responding tumors should have CD8+ T-cell infiltration and at least a subset of tumor-infiltrating CD8+ T cells display properties that can respond to anti-PD1. The gene discussed is CD8A; the disease is colorectal neoplasm.